Amplification of the epidermal growth factor receptor (EGFR) or expression of its constitutively activated mutant, DEGFR(2-7), in association with the inactivation of the INK4a/Arf gene locus is a frequent alteration in human glioblastoma. The notion of a cooperative effect between these two alterations has been demonstrated in respective mouse brain tumor models including our own. Here, we investigated underlying molecular mechanisms in early passage cortical astrocytes deficient for p16
Introduction
Glioblastoma multiforme, the most malignant astrocytic tumor, may progress from a lower grade astrocytoma or may arise de novo without clinical or histological evidence of a less malignant precursor lesion. Amplification of the epidermal growth factor receptor (EGFR) gene constitutes a hallmark of de novo glioblastomas (40-60%) and is frequently associated with deletion of the INK4a/Arf gene locus (Hayashi et al., 1997; Hegi et al., 1997) . Rearrangements of the EGFR gene occur in 20% of glioblastoma (Wong et al., 1992) . A common rearrangement leads to splicing out of exons 2-7, DEGFR(2-7), also known as EGFRvIII, causing a constitutive activation of the receptor. Ectopic expression of this mutant has been shown to confer a growth advantage to the glioblastoma cell line U87MG in vitro under low serum conditions and enhanced tumorigenicity when implanted orthotopically into nude mice (Nishikawa et al., 1994) . EGFR overexpression or expression of the truncated mutant DEGFR(2-7) lead to the activation of the PI3K/PKB/Akt (Moscatello et al., 1998; Choe et al., 2003) or Ras/MAPK pathways (Montgomery et al., 1995; Prigent et al., 1996; Guha et al., 1997; Rajasekhar et al., 2003) . In human glioblastoma EGFR overexpression and INK4a/Arf deletion are almost mutually exclusive with TP53 mutations (Watanabe et al., 1996; Fulci et al., 2000) suggestive of a cooperative effect between an activated EGFR pathway and an inactive INK4a/Arf gene locus. The INK4a/Arf gene locus encodes two tumor suppressors, p16
INK4a and p19 Arf (p14 Arf in humans), translated from alternatively spliced mRNAs (Quelle et al., 1995) . p16
INK4a prevents the formation of the complex CDK4 and cyclin D1, which maintains RB1 in its active, antiproliferative state, thus preventing G1 entry (Serrano et al., 1993) , while p19
Arf stabilizes p53 through binding to Mdm2 (Weber et al., 1999) . p53 is activated and accumulates in the cell nucleus in response to various cellular stress such as DNA damage, hypoxia, and oncogene activation (Levine, 1997) . In turn, p19
Arf has been shown to be induced by inappropriate mitogenic signals, for example, through Myc, Ras, or E2F (Sherr and McCormick, 2002) , thus activating the p53 pathway in response to oncogene activation. The activation of p19
Arf may not only be mediated by E2F1-and E2F2-dependent but also -independent mechanisms (Palmero et al., 2002) . Hence, p19 Arf inactivation may be in part redundant with p53 alteration. However, recent studies suggest that p19
Arf may have also p53-independent tumor suppressing functions by inducing G2 arrest and apoptosis (Eymin et al., 2003) , and mouse models have shown that inactivation of p19
Arf and p53 may collaborate in the progression of certain tumor types (Kamijo et al., 1997) . Cell-type-specific roles in growth control and immortalization have been established for p16 INK4a and p19 Arf (Sharpless et al., 2004) . Both need to be inactivated in astrocytes to avoid senescence (Bachoo et al., 2002) . Deletion of the INK4a/Arf gene locus is an effective way to target simultaneously the pRb/CDK4/ p16
INK4a and p53 pathways of tumor suppression in a single step. It has been shown that inactivation of the pRb/CDK4/p16
INK4a pathway, affecting G1-S transition control, is associated with an altered p53 pathway in virtually all glioblastomas (96%). Usually, only one component from each pathway is affected. Some combinations, however, are selected for in vivo, for example, RB1 mutations are associated with mutations in the TP53 gene (Ichimura et al., 2000) .
Small molecule drugs have been developed to target specifically EGFR to prevent downstream signaling (Mendelsohn and Baselga, 2000) . Tyrphostin AG1478 inhibits the receptor tyrosine kinase (RTK) by binding to the substrate binding site and prevents the autophosphorylation of the receptor. Structurally, it resembles tyrosine and has hydrophobic characteristics that allow it to readily cross the cell membrane. AG1478 is a highly specific inhibitor for EGFR without crossinhibition of other members of the RTK family, such as ERBB2/Neu or PDGFR (Levitzki and Gazit, 1995) . Moreover, AG1478 not only acts on the wild-type form but was also highly effective in inhibiting human glioma cells expressing the common rearranged form, DEGFR(2-7) (Han et al., 1996) . An additive effect of tyrphostin AG1478 treatment has been demonstrated for CD95L-induced cell death in human glioma cell lines ectopically expressing EGFR (Steinbach et al., 2002) . Similarly, it sensitized human glioblastoma xenografts expressing DEGFR(2-7) to cytotoxic effects of cisplatin (Nagane et al., 2001) .
Taking in vivo and in vitro approaches, we aimed at investigating the potential cooperative effect between INK4a/Arf deletion and the activation of the EGFR signaling pathway, and their respective underlying molecular mechanisms in the context of their relevance for glioma genesis. The cooperative effect was successfully modeled in vivo by means of a neurografting paradigm. Using a panel of astrocytic cell lines derived from newborn mice with the respective genotypes (INK4a/Arf-KO (Serrano et al., 1996) , TP53-KO (Donehower et al., 1992), INK4a/Arf_TP53-KO) or brain tumor cell lines derived from our mouse models, we set out to identify relevant biological processes favored by the apparent cooperative effect selected for in human glioblastoma. We tested DEGFR(2-7) as a survival factor in cooperation with an inactivated INK4a/Arf gene locus in an anoikis model and in response to treatment with the specific EGFR inhibitor tyrphostin AG1478. While the anoikis model provided no insight into this cooperative mechanism, inactivation of EGFR by tyrphostin AG1478 revealed that subsequent abrogation of signaling through ERK was dependent on the presence of an intact INK4a/Arf gene. This finding might be of crucial clinical relevance since first trials reported the apparent lack of a correlation between the EGFR status and response to the specific EGFR inhibitor Iressa in glioblastoma patients (Rich et al., 2004) .
Results
INK4a/Arf inactivation cooperates with DEGFR(2-7) expression in vivo To model the cooperating potential between INK4a/Arf inactivation and an active EGFR pathway for gliomagenesis in vivo, we have established a glioblastoma mouse model using a neurografting paradigm as described before for TP53 inactivation . This model is based on orthotopic transplantation of neuroectodermal cells, either INK4a/Arf hemizygous or INK4a/Arf-KO (Serrano et al., 1996) , and retrovirally transduced with either EGFR, DEGFR(2-7), or an empty vector. Tumors were exclusively obtained in the group of transplants derived from INK4a/Arf-KO neuroectodermal cells and transduced with DEGFR(2-7), yielding four tumors per 44 (9%) transplants within the observation period of 1 year (Table 1) . Neither transplantation of INK4a/Arf-KO neuroectodermal cells alone nor transduced with wildtype EGFR, nor INK4a/Arf hemizygous neuroectodermal cells transduced with either DEGFR(2-7) or wildtype EGFR had the potential to trigger glioma development in this low penetrance brain tumor model. These results are in line with a cooperative transforming potential of DEGFR(2-7) in vivo in association with an inactivated INK4a/Arf gene locus. Further, no TP53 mutation could be detected by direct sequencing of the cDNA covering exons 4-10 in the three tumors analysed. Applying the criteria of the human tumor classification (Kleihues and Cavenee, 2000) , two neoplasms displayed morphologic features of glioblastoma, including invasiveness, and tumor necrosis (Figure 1 ), while the other two tumors showed features of a primitive neuroectodermal tumor. The same tumor spectrum was observed in the respective brain tumor model for TP53 inactivation . The neoplastic lesions were rapidly growing necessitating to kill the tumor-bearing mice 2-4 months after transplantation. Cell lines were derived from the three largest tumors with diameters between 5 and 9 mm (LN-m980, LN-m992, LN-m996). The cell lines proved to be highly tumorigenic upon subcutaneous injection of 10 Â 10 6 cells into the flanks of nude mice (volume of 2 cm 3 within Overall gene expression profiles were obtained on cDNA arrays from the three tumors induced in this INK4a/Arf-KO and DEGFR(2-7) glioma mouse model (980, 992, 996) and two tumors derived from the TP53-KO brain tumor model described previously (7156 and 4801) . The 406 genes passing a variation filter were analysed by coupled two-way clustering (CTWC) (Getz et al., 2000; Godard et al., 2003) . With this limited number of samples available that certainly restricts the conclusions due to statistical considerations, we identified 16 stable gene clusters. Cluster 15 comprising 11 genes particularly attracted our attention, because reclustering of the tumor samples by the expression of these genes separated the tumors into two groups according to their origin INK4a/Arf-KO and DEGFR(2-7) and TP53-KO, respectively ( Figure 2a ). These genes are relatively overexpressed in the gliomas induced by p16 INK4a 
/p19
Arf deficiency and DEGFR(2-7) expression and encode proteins involved in the cell cycle (cyclins D1 and D2, cdc42) and cell adhesion and migration (Ly68, MMP15, syndecan 3, and cytoplasmic b-actin, cdc42, P2Y) (Short et al., 2000; Cheng et al., 2004) . The higher abundance of cyclin D1 and D2 in the INK4a/Arf-KO-and DEGFR(2-7)-derived gliomas was subsequently confirmed by immunohistochemistry on the respective tumor sections with high nuclear expression in over 60% of the tumor cells in contrast to only 10 and 30% in the two TP53-KO gliomas (Figure 2b and c). Interestingly, four members of this gene cluster, cyclin D1 and D2, cdc42, and P2Y are either functionally linked or downstream members of the RTK-activated MAP-kinase or PI3-kinase pathways. These gene expression based differences between the two tumor models may suggest qualitative differences in the MAPK and PI3K pathways.
DEGFR(2-7) does not protect INK4a/Arf-KO astrocytes from anoikis
Glioblastomas are highly invasive tumors and respective neoplastic cells are believed to acquire the capability to survive in the absence of appropriate extracellular matrix (Davies et al., 1998; Koul et al., 2001 ). Hence, we tested the ability of DEGFR(2-7) to act as a survival factor in anoikis in cooperation with an inactive INK4a/ Arf gene locus. In order to avoid the influence of additional genetic alterations associated with tumor cell lines in this experiment, we established early passage primary astrocytes from the respective null mice. Primary cortical astrocytes derived from newborn mice INK4a/Arf-KO and transduced with DEGFR(2-7) were cultured under forced suspension and evaluated for DEGFR(2-7)-mediated resistance to anoikis over 24 h. Ectopic expression of DEGFR(2-7) in INK4a/Arf-KO astrocytes did not confer any resistance to anoikis ( Figure 3 ). DEGFR(2-7) inhibition by tyrphostin AG1478 reduces ERK phosphorylation only in the presence of an intact INK4a/Arf gene Next, we investigated the effect of the specific kinase inhibitor on EGFR downstream signaling through the Ras/ERK and the PKB/Akt pathways, respectively. We abolished DEGFR(2-7) activation (phosphorylation) using tyrphostin AG1478 and determined its effect on ERK phosphorylation after 24 h. Phosphorylation of ERK was not altered upon treatment with tyrphostin AG1478 in both INK4a/Arf-KO and INK4a/Arf_TP53-KO astrocytes, regardless of the presence or absence of DEGFR(2-7) expression. However, ERK phosphorylation was inhibited in TP53-KO astrocytes that carry an intact INK4a/Arf gene locus, suggesting a genotypedependent difference in the inhibition of this pathway ( Figure 4 ). Thus, lack of INK4a/Arf in astrocytes seemed to prevent the inhibition of ERK phosphorylation through tyrphostin AG1478 treatment. No difference in PKB/Akt activation associated with tyrphostin AG1478 exposure could be observed in either TP53-KO or INK4a/Arf-KO astrocytes (data not shown), suggesting that the effect of tyrphostin AG1478 was effective on ERK signaling.
To test the relevance of these observations obtained in primary astrocytes, we turned to a model system that evolved through a selection process in vivo. We took advantage of the three glioma cell lines (LN-m980, LNm992, LN-m996) derived from the brain tumor mouse model described here, and of a TP53-KO cell line, ZHm7156, established from the respective mouse brain tumor model for TP53 inactivation . These cell lines comprise genetic alterations selected during tumorigenesis in vivo that cooperate or are additive to the initial genetic alterations introducedINK4a/Arf-KO and DEGFR(2-7) or TP53-null, respectively -aiming at modeling pathogenetic pathways of . Genes passing a variation filter (n ¼ 406) were submitted to CTWC. A stable cluster comprising 11 genes (G15) was identified, which when the samples were reclustered accordingly separated INK4a/Arf-KO and DEGFR(2-7) and TP53-KO derived tumors, as depicted in the dendrogram displayed using Treeview Software (http://rana.stanford.edu/software) (Eisen et al., 1998) (a) . Immunohistochemistry confirmed the relative overexpression of cyclin D1 and cyclin D2 in tumor 996 (INK4a/Arf-KO and DEGFR(2-7)) with high levels of nuclear cyclin D1/2 in over 60% of the cells (b), while in tumor 4801 (TP53-KO) cyclin D1/2 expression was only detectable in 10% of cell nuclei (c) Figure 3 Expression of DEGFR(2-7) does not provide resistance to anoikis in early passage astrocytes deficient for p16
INK4a /p19
Arf . Astrocytes derived from newborn mice INK4a/Arf-KO retrovirally transduced with DEGFR(2-7) or an empty vector were cultured in low serum conditions for 4, 8, and 24 h on polyHEMA-treated flasks. Resistance to anoikis was measured as cell survival using the MTT test. Survival is normalized to untreated astrocytes at time 0, considered as 100% survival. Histograms represent means of three independent experiments and their respective standard deviation. Staurosporine-treated cells served as positive controls for apoptosis Figure 4 Western blot analysis of phospho-ERK and phospho-EGFR treated with tyrphostin AG1478. Astrocytes, INK4a/Arf-KO, TP53-KO or INK4a/Arf_TP53-KO, and retrovirally transduced with DEGFR(2-7) or the empty vector were cultured for 24 h in the presence or absence of 5 mM tyrphostin AG1478 under low serum conditions. This noncytoxic dose of tyrphostin AG1478 efficiently inhibited phosphorylation of ectopically expressed DEGFR(2-7). Phosphorylation of ERK was not changed upon treatment with tyrphostin AG1478 in both INK4a/Arf-KO and INK4a/Arf_TP53-KO astrocytes in the presence or absence of DEGFR(2-7) expression. In contrast, ERK phosphorylation was significantly reduced in TP53-KO astrocytes that carry an intact INK4a/Arf gene locus INK4a/Arf is required for EGFR pathway inactivation Y Lachat et al primary and secondary glioblastoma development. Treatment with tyrphostin AG1478 for 24 h blocked phosphorylation of DEGFR(2-7) and also of the respective endogenous wild-type EGFR detectable in all four lines. However, tyrphostin AG1478 was incapable of inhibiting ERK phosphorylation in the three tumor cell lines INK4a/Arf-KO and DEGFR(2-7) (LNm980, LN-m992, and LN-m996) . In contrast, the TP53-KO brain tumor cell line ZH-m7156 exhibited suppression of ERK phosphorylation under tyrphostin AG1478 treatment ( Figure 5 ). The presence of the INK4a/Arf gene locus was confirmed in this cell line by PCR. Taken together, the results obtained in the tumor cell lines are in line with the observations in the early passage astrocytes. INK4a/Arf loss appears to block the inhibition of ERK signaling by tyrphostin AG1478 treatment, thus uncoupling EGFR/DEGFR(2-7) signaling upstream of ERK.
Subsequently, we evaluated the effect of tyrphostin AG1478 on growth in vitro over 12 days with regard to the INK4a/Arf and DEGFR(2-7) status in the respective astrocyte lines. Ectopic expression of DEGFR(2-7) resulted in increased growth under low serum conditions regardless of the INK4a/Arf or TP53 status, respectively. This DEGFR(2-7)-mediated growth induction could be inhibited by tyrphostin AG1478 also in a genotype-independent manner (Figure 6 ), while in the absence of DEGFR(2-7), no effect was observed at a dose of 5 mM. Thus, suggesting that tyrphostin AG1478 specifically inhibited DEGFR(2-7)-mediated growth induction at a noncytotoxic concentration preventing autophosphorylation of DEGFR(2-7), as determined by Western blot at 24 h (Figures 4 and 5) . Despite the observation that treatment with tyrphostin AG1478 for 24 h was incapable to inactivate ERK in the absence of an intact INK4a/Arf gene locus, DEGFR(2-7)-mediated growth was specifically inhibited by the EGFR inhibitor as observed over 12 days. This may suggest that growth stimulation through the EGFR may also be mediated by other than the Ras/ERK and the PKB/Akt pathways. Locking ERK into an active state likely contributes to the cancer process by other means than simple growth induction.
Discussion
Our in vivo and in vitro efforts have provided several lines of evidence for a functional cooperative effect between an abrogated INK4a/Arf gene locus and a constitutively activated EGFR signaling pathway important for the progression of glioblastoma, but possibly also of crucial clinical relevance for subsequent treatment. Such a cooperative effect has been suspected based on the respective molecular correlation observed in human glioblastoma (Hayashi et al., 1997; Hegi et al., 1997 ) and a mouse model yielding glioma-like lesions by expressing a constitutively active EGFR in a nestindependent manner in an INK4a/Arf-KO genetic background (Holland et al., 1998) . Recent work by Bachoo et al. (2002) suggests that EGFR expression in INK4a/ Arf-KO astrocytes leads to a dedifferentiated phenotype, while in respective neural stem cells the undifferentiated status is maintained leading to a common high-grade phenotype regardless of the cell of origin. Our low penetrance brain tumor model described here is in agreement with these observations. However, respective underlying molecular mechanisms for this cooperation are poorly understood.
We aimed at identifying biological processes favored by this cooperating effect that are of relevance for glioma progression. No such insights, however, emerged from our investigations testing the activated EGFR pathway as a survival factor in an anoikis model in relation to the INK4a/Arf status. This effort was based on the rational that gliomas are diffusely invading tumors and preferentially overexpressing EGFR in the periphery (Okada et al., 2003) that in turn may render Figure 5 Western blot analysis of phospho-ERK and phospho-EGFR on tumor-derived cell lines treated with tyrphostin AG1478. (a) Tyrphostin AG1478 treatment inhibits phosphorylation of DEGFR(2-7) in the mouse glioma cell line LN-m992 in a dosedependent manner. (b) Tumor cell lines derived from our brain tumor mouse models, LN-m980, LN-m992, and LN-m996, INK4a/ Arf-KO that express DEGFR(2-7) and ZH-m7156, TP53-KO, were treated for 24 h with 5 mM tyrphostin AG1478 under low serum conditions. Inhibition of DEGFR(2--7) by tyrphostin AG1478 leads to a reduction of ERK signaling only in ZH-m7156 that has retained INK4a/Arf. The tyrphostin AG1478 treatment inhibited phosphorylation of DEGFR(2-7) and the endogenous wt-EGFR, which is detectable in all cell lines. Please note, detection of phospho-EGFR expression in cell line ZH-m7156, framed in black, is displayed with a longer film exposure than the remainder of the Western blot INK4a/Arf is required for EGFR pathway inactivation Y Lachat et al tumor cells permissive for survival on an inappropriate extracellular matrix. Subsequent investigations dissecting the signaling pathway revealed that specific inhibition of the EGFR in the absence of an intact INK4a/Arf gene locus modulated downstream signaling. Dephosphorylation of ERK following treatment with the specific EGFR inhibitor tyrphostin AG1478 was dependent on the presence of an intact INK4a/Arf gene locus. Thus, it suggested that deletion of the INK4a/Arf gene locus resulted in sustained EGFR downstream signaling, demonstrated here by the insensitivity to inhibit ERK phosphorylation. This effect was observed in early passage astrocytes derived from newborn mice of the respective genotypes independent of DEGFR(2-7) transduction. This model was used to minimize interfering contributions by other acquired molecular alterations. The relevance of this finding was further emphasized by subsequent confirmation of the requirement of the INK4a/Arf gene locus for deactivation of ERK upon inhibition of the EGFR in cell lines established from our mouse brain tumor models. In line with our findings is a recent report showing resistance to block downstream signaling through ERK or PKB/Akt using several small molecule EGFR inhibitors regardless of ectopic EGFR expression in human glioblastoma cell lines (Li et al., 2003) . With one exception, all these glioblastoma cell lines are deleted for the INK4a/Arf gene locus as reported previously from our lab (Ishii et al., 1999) . Further, it has been shown that the phosphorylated form of ERK is elevated in all human glioblastoma (Rajasekhar et al., 2003) regardless of the EGFR status. However, there might be qualitative differences in the regulation of downstream signaling in the MAP-kinase pathway, which depend on other underlying genetic alterations as illustrated by differential expressions of cylin D1 and D2, cdc42, and PY2 in our two distinct glioma models, not reflected in the extent of ERK or PKB/Akt phosphorylation. Such mechanisms may explain that specific inhibition of growth induction conferred by DEGFR(2-7) could be inhibited without detectable changes of PKB/Akt or ERK phosphorylation. Further, EGFR/DEGFR(2-7)-mediated mitogenic stimuli may also be transmitted by other than the PI3K/PKB/Akt or the Ras/MAPK pathway.
These observations may establish a new role for p16 INK4a and p19 Arf in the inhibition of EGFR downstream signaling, possibly in a negative feedback loop of the Ras/MAPK pathway to regulate mitogenic stimuli. Alternatively, inactivation of the INK4a/Arf gene locus could release suppression of another pathway activating ERK. Both would explain the efficiency of tyrphostin AG1478 treatment to decrease drastically ERK phosphorylation in the tumor cell line ZH-m7156 that is null for p53 but carries an intact INK4a/Arf gene locus. Thus the underlying molecular mechanism is p53 independent. It will be of importance to investigate p16
INK4a and p19
Arf function in the context of negative regulation of the RTK-induced MAPK pathway such as mediated by sprouty proteins. Sprouty 1 and 2 provide a control mechanism by inhibiting the recruitment of the Grb2-Sos complex or binding to Raf (Reich et al., 1999; Hanafusa et al., 2002) . More recently sprouty proteins have also been shown to have positive regulatory effects that are mediated by binding of c-Cbl to phosphorylated sprouty or respective target proteins (Christofori, 2003) . However, the regulatory molecular mechanisms determining respective sprouty function are complex and poorly understood.
The relative roles of the two gene products encoded for by INK4a/Arf in cancer are known to be cell-type, mouse strain, and species specific (Sharpless et al., 2004) . However, several lines of evidence suggest that inactivation of both p16
INK4a and p19 Arf is of importance for the development of astrocytic tumors. Both need to be inactivated to prevent senescence of astrocytes in vitro and for cooperation with activated EGFR according to Figure 6 Inhibition of DEGFR(2-7)-mediated growth by tyrphostin AG1478 in astrocytes. Astrocytes, INK4a/Arf-KO and TP53-KO transduced retrovirally with DEGFR(2-7) or the respective control vector were cultured up to 12 days under low serum conditions in the presence (&) or absence of tyrphostin AG1478 (') (5 mM). Growth was estimated colorimetrically (OD 550 ) after crystal violet treatment. Time points represent quadruplicate plating and their standard deviation. Tyrphostin AG1478 treatment abolished growth induction conferred by DEGFR(2-7) expression regardless of the INK4a/Arf or TP53 status. In the absence of DEGFR(2-7), no effect on growth was observed; thus, suggesting a specific effect of tyrphostin AG1478 at a noncytotoxic dose an orthotopic brain tumor model (Bachoo et al., 2002) . This necessity to inactivate both gene products has been shown to be a cell-type-specific feature of astrocytes, (Sharpless et al., 2004) . Furthermore, in human glioblastoma p16
INK4a and p14 Arf (human homolog for p19
Arf ) are always coinactivated by deletion of the entire INK4a/Arf gene locus (Ichimura et al., 2000; Labuhn et al., 2001) . In contrast, in breast cancer in which methylation is a major mechanism of inactivation that may allow selective silencing of either p16
INK4a or p14 Arf , although no conclusive results have been shown to that end. Inactivation of the INK4a/Arf gene locus may not only affect the formation of the cyclin D1/CDK4/6 complex regulated by p16
INK4a (Serrano et al., 1993) and avoid p19
Arf -dependent induction of the p53 pathway, both of which are essential to render tumor cells permissive to activated oncogenes (Zou et al., 2002) , but may also provide an additional growth advantage. Beside the fact that p16
INK4a and p19 Arf are induced through the MAP-kinase pathway due to activated oncogenes, both are capable individually to reduce the abundance of cyclin D1 (D'Amico et al., 2003) , which is in line with our results from our glioma models on RNA and protein levels. These interactions that are not well known may contribute to the cooperative tumorigenic effect selected for in human in glioblastoma. There is evidence that the relevance of this negative regulatory mechanism for tumor progression might not only be cell-type specific but also depends on the pathogenetic pathway(s) employed. Indeed, primary glioblastoma seem to select for loss of the entire INK4a/Arf gene locus that is mutually exclusive with TP53 mutations (Fulci et al., 2000; Labuhn et al., 2001) . In contrast, the inactivation of the INK4a/Arf locus frequently coexists with TP53 mutations in non-small-cell lung cancer (NSCLC) (Gazzeri et al., 1998; Sanchez-Cespedes et al., 1999) that also frequently exhibit an activated EGFR pathway mediated by EGFR overexpression (62%) (Haeder et al., 1988) and DEGFR(2-7) expression (39%) (Okamoto et al., 2003) . It remains to be shown which gene product of the INK4a/Arf gene locus, that p16
INK4a -or a p53-independent function of p19 Arf was recently postulated (Kuo et al., 2003) , mediates the negative regulation responsible for the sensitivity to downregulate ERK activity upon inhibition of activated EGFR.
Our findings might be of pertinent clinical relevance, in light of a first publication (Rich et al., 2004) on a phase II trial testing the EGFR inhibitor Iressa in recurrent glioblastoma. The study showed that response to treatment was not correlated with the expression of the EGFR. This lack of correlation may possibly be explained by resistance conferred by INK4a/Arf deletions known to be associated with DEGFR(2-7)/EGFR overexpression in glioblastoma, while tumors retaining INK4a/Arf may show some responsiveness even in the absence of dramatic EGFR overexpression as detectable by immunohistochemistry. However, drug concentrations insufficient for consistent inactivation of the receptor in some patients cannot be excluded since drug levels reaching the target were not monitored. It follows that activity of signaling pathways, their respective downstream mediators, and cooperating molecular alterations need to be evaluated for their impact on responsiveness to respective targeted treatments.
Material and methods

Retroviral vectors and plasmids
The ecotropic, replication-defective retroviral vectors pLXSN.EGFR and pLXSN.DEGFR(2-7) were constructed by excising the human EGFR or DEGFR(2-7) with XbaI and XhoI from pSK.EGFR or pSK.DEGFR(2-7) (generous gifts from HJ Su Huang; Nishikawa et al., 1994) , respectively, and cloning into BamHI site of the pLXSN vector (Clontech, Palo Alto, CA, USA). The constructs were transfected into the GP þ E86 packaging cell line. Clones were picked after selection. The supernatant was collected, filtered (45 mm), and always used fresh. The clones used in the experiments produced a titer of 10 6 colony-forming units/ml, as determined by titration in NIH3T3 cells. The retrovirus (pLXSN) without insert yielded a similar titer and was used as a control vector. Supernatants with the amphotropic retroviral vectors 1726Zeo and 1726Zeo.DEGFR(2-7) were kindly provided by O Bo¨gler (Chen et al., 2000) .
Cell lines
Cell lines (GP þ E86) (Markowitz et al., 1988) , LNm980, LN-m992, LN-m996, and ZH-m7156, and primary cortical astrocytes were maintained in highglucose DMEM (Invitrogen Corporation, Basel, Switzerland) containing 10% fetal calf serum (FCS) (BioConcept, Allschwil, Switzerland) and penicillin/ streptomycin (100 U/100 mg/ml; Invitrogen Corporation). All functional experiments were conducted under low serum conditions of 0.5% FCS.
Tumorigenicity assay
A total of 10 million cells were subcutaneously injected into the flank of Swiss nude mice (Charles River France, France), five mice per cell line. Tumor growth was monitored once a week with a caliper. Mice were killed after tumors reached the volume of 2 cm 3 . Tumor volume was calculated according to the following formula: V ¼ 
Brain tumor model
Isolation, infection, and stereotaxic transplantation of neuroectodermal cells was performed as described previously . In brief, female INK4a/ Arf heterozygous mice (Serrano et al., 1996) were mated with INK4a/Arf-KO mice. On day 13.5 of gestation, neuroectodermal cells from individual fetal brains were isolated and plated in six-well plates with 2 ml fresh, virus-containing supernatant. After 20 h of infection, neuroectodermal cells were trypsinized, washed, and covered with DMEM. Pelleted neuroectodermal cells derived from individual embryos were injected with a 25 ml syringe (#1702, Hamilton, Bonaduz, Switzerland) into the caudoputamen (coordinates: bregma 0/0, right þ 2.5 mm, depth 3 mm; stereotaxic frame, Stoelting) of 8-week-old anesthesized mice (F1: 129SvEv Â C57BL/6; reflecting the genetic make-up of the donor mice). Cells remaining in the syringe after transplantation were replated to test viability, to determine efficacy of retroviral infection and expression levels of EGFR or DEGFR(2-7), respectively. The genotypes of the transplanted cells were determined by analysing tail DNA of the respective embryos by PCR (Serrano et al., 1996) .
Isolation and infection of primary cortical astrocytes derived from newborn mice
Primary cortical astrocytes were prepared and selected according to the protocol published by Bo¨gler et al. (1995) . Primary astrocytes derived from INK4a/Arf-KO, TP53-KO (Donehower et al., 1992) , and the respective intercross were retrovirally transduced at passage 5 with the vector 1726Zeo or 1726Zeo.DEGFR(2-7) in the presence of 8 mg/ml polybren (Sigma, Buchs, Switzerland) for 2 h. Selection was performed in the presence of 250 mg/ml Zeocin (Invitrogen Corporation, Basel, Switzerland). Wild-type astrocytes were not used in the experiments, since they exhibited a completely different growth behavior with a quiescent phenotype.
Analysis of grafts and tumors by immunohistochemistry, TP53 mutation analysis
Mice were killed 1 year post-transplantation or immediately after the development of neurological symptoms. The brain was extracted, formalin fixed, and paraffin embedded for histology. Macroscopically visible tumors were put in culture to derive cell lines as described previously (Diserens et al., 1981) . Immunohistochemistry was performed under standard conditions using a heat epitope retrieval method in citrate buffer (pH 6.0; 3 min in pressure cooker) with the exception for GFAP (anti-EGFR, 1 : 200, sc-03 1005, Santa Cruz, CA, USA; anti-GFAP, 1 : 200, Z0334, Dako, Glostrup, Denmark; anti-cyclin D1/2, 1 : 500, 05-362, Upstate, Lake Placid, NY, USA). Diaminobenzidine (Vectastain ELITE VECTOR Mouse Ig-6102 kit) was used for revelation followed by counterstaining with Gill's hematoxylin. The TP53 gene was analysed for mutations by direct sequencing (Microsynth GmbH, Balgach, Switzerland) of exons 4-10 of the TP53 cDNA amplified from the tumors as described (Magnusson et al., 1998) .
Gene expression profiling
Atlas Mouse Cancer 1.2 Arrays (Clontech Laboratories) with 1185 spotted genes, mostly related to cancer, were used to obtain gene expression profiles from five fresh frozen intracranial tumors obtained in the Ink4a/ Arf-KO and DEGFR(2-7) and the TP53-KO brain tumor model. DNase-treated total RNA (3-5 mg) were used to prepare a labeled first-strand cDNA using the Clontech kit. Experiments and data analysis were performed as described previously (Godard et al., 2003) . The gene expression profile obtained from a normal brain of a wild-type mouse served as reference for data analysis. CTWC (Getz et al., 2000) was performed online (http://ctwc.weizmann.ac.il) using 406 genes that passed a variation filter of two in at least one sample.
Induction of anoikis
Cells were adapted to low serum conditions for 24 h. Subsequently, 10 6 cells were resuspended in 4 ml low serum medium on poly-(2-hydroxyethyl methacrylate)-(Sigma) coated flasks (Folkman and Moscona, 1978) in the presence or absence of 2.5 mM staurosporine (Sigma). Cells were plated for survival analysis or processed for Western blotting after 0, 4, 8, and 24 h, respectively. For cell survival analysis, single-cell suspensions were distributed in triplicate into a 96-well plate and serial dilutions (1 : 2) were performed. Cells were allowed to adhere for 1 h and were then incubated with 25 ml methotrexate (MTT, Sigma, 5 mg/ml) for 3 h. Optical density was measured at 550 nm in an ELISA reader. The means of triplicate time points were taken and normalized to nontreated cells at time 0 (considered as 100% of survival).
Treatment with EGFR inhibitor
For growth curves, cells were preincubated for 24 h under low serum conditions in the presence or absence of 5 mM tyrphostin AG1478 (Calbiochem, Schwalbach, Germany). In total, 10 000 astrocytes (passage 12) were then plated in quadruplicate in a 24-well plate. Cells were grown in the presence or absence of 5 mM tyrphostin AG1478 under low serum conditions for up to 12 days. The medium was changed every 2 days. Cells were rinsed twice with phosphate-buffered saline and incubated for 5 min with 0.1% crystal violet in H 2 O (Merck, Darmstadt, Germany). Crystals were dissolved in 1% sodium dodecyl sulfate (SDS) in H 2 O. Absorbance was measured at 550 nm.
Western blot analysis
Immunoblots were conducted according to standard procedures. Cells were lysed in 1 Â SDS sample buffer (62.5 mM Tris/HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM DTT, 0.01% bromophenol blue). Total protein concentration was determined using the Bradford Assay (Bio-Rad, Hercules, CA, USA). Protein extracts (25 mg) were run on an SDS-polyacrylamide gel electrophoresis. Antibodies were used at the following dilutions: rabbit anti-phospho-EGFR (1 : 1000, #2234), rabbit anti-phospho-PKB/Akt (1 : 1000, #9271), rabbit anti-PKB/Akt (1 : 1000, #9272), rabbit anti-phospho-ERK (1:1000, #9101), rabbit anti-ERK (1 : 1000; #9102, Cell INK4a/Arf is required for EGFR pathway inactivation Y Lachat et al Signaling, Beverly, MA, USA), rabbit anti-EGFR (1 : 1000; sc-03 1005, Santa Cruz Biotechnology, CA, USA), mouse anti-tubulin (1 : 2000, T5168). Revelation of immunoblots was performed with horseradish peroxidase-coupled species-specific antibodies (goat antimouse IgG (1 : 10000; A-2304, Sigma, St Louis, MO, USA), goat anti-rabbit (1 : 10000; Nordic Immunological Laboratories, Tilburg, The Netherlands) against the primary antibody, followed by chemoluminescence detection (Roche Diagnostics, Mannheim, Germany).
